Skip to main content

Research Repository

Advanced Search

Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial

Flaherty, Katie; Bath, Philip M.W.; Dineen, Robert; Law, Zhe; Scutt, Polly; Pocock, Stuart; Sprigg, Nikola

Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial Thumbnail


Authors

Katie Flaherty

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine

ROBERT DINEEN rob.dineen@nottingham.ac.uk
Professor of Neuroradiology

Zhe Law

Polly Scutt

Stuart Pocock

NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
Professor of Stroke Medicine



Abstract

Rationale

Aside from blood pressure lowering, treatment options for intracerebral haemorrhage remain limited and a proportion of patients will undergo early haematoma expansion with resultant significant morbidity and mortality. Tranexamic acid (TXA), an anti-fibrinolytic drug, has been shown to significantly reduce mortality in patients, who are bleeding following trauma, when given rapidly. TICH-2 is testing whether TXA is effective at improving outcome in spontaneous intracerebral haemorrhage (SICH).
Methods and design

TICH-2 is a pragmatic, phase III, prospective, double-blind, randomised placebo-controlled trial. Two thousand adult (aged ≥ 18 years) patients with an acute SICH, within 8 h of stroke onset, will be randomised to receive TXA or the placebo control. The primary outcome is ordinal shift of modified Rankin Scale score at day 90. Analyses will be performed using intention-to-treat.
Results

This paper and its attached appendices describe the statistical analysis plan (SAP) for the trial and were developed and published prior to database lock and unblinding to treatment allocation. The SAP includes details of analyses to be undertaken and unpopulated tables which will be reported in the primary and key secondary publications. The database will be locked in early 2018, ready for publication of the results later in the same year.
Discussion

The SAP details the analyses that will be done to avoid bias arising from prior knowledge of the study findings. The trial will determine whether TXA can improve outcome after SICH, which currently has no definitive therapy.
Trial registration

ISRCTN registry, ID: ISRCTN93732214. Registered on 17 January 2013.

Citation

Flaherty, K., Bath, P. M., Dineen, R., Law, Z., Scutt, P., Pocock, S., & Sprigg, N. (in press). Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial. Trials, 18(1), Article 607. https://doi.org/10.1186/s13063-017-2341-5

Journal Article Type Article
Acceptance Date Nov 9, 2017
Online Publication Date Dec 20, 2017
Deposit Date Jan 3, 2018
Publicly Available Date Jan 3, 2018
Journal Trials
Electronic ISSN 1745-6215
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 18
Issue 1
Article Number 607
DOI https://doi.org/10.1186/s13063-017-2341-5
Keywords Hyperacute; Spontaneous intracerebral haemorrhage; Tranexamic acidRandomised trial; Placebo-controlled
Public URL https://nottingham-repository.worktribe.com/output/900939
Publisher URL https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2341-5
Contract Date Jan 3, 2018

Files





You might also like



Downloadable Citations